A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

Paul F. Robbins, Mona El-Gamil, Yong F. Li, Yutaka Kawakami, Douglas Loftus, Ettore Appella, Steven A. Rosenberg

Research output: Contribution to journalArticle

434 Citations (Scopus)

Abstract

A number of antigens recognized by tumor-reactive T cells have recently been identified. The antigens identified in mouse model systems appear, with one exception, to represent thee products o mutated genes. In contrast, most of the antigens recognized by human tumor-reactive C cells reported to date appear to represent the products of non-mutated genes. Here we report the isolation o a cDNA clone encoding β-catenin, which was shown to be recognized by the tumor-infiltrating lymphocyte (TIL) 1290, a HLA-A24 restricted melanoma-specific CTL line from patient 888. Thee cDNA clone, which was isolated from thee autologous melanoma cDNA library, differed by a single base pair from the published β-catenin sequence, resulting in a change from a serine to a phenylalanine residue at position 37. Normal tissues from this patient did not express the altered sequence, nor did 12 allogeneic melanomas, indicating that this represented a unique mutation in this patient's melanoma. A peptide corresponding to the sequence between amino acids 29 and 37 of the mutant gene product was identified as the T cell epitope recognized by TIL 1290. The observation that HLA-A24 binding peptides contain an aromatic or hydrophobic residue at position 9 suggested that the change at position 37 may have generated a peptide (SYLDSGIHF) which was capable of binding to HLA-A24, and a competitive binding assay confirmed this hypothesis. The β-catenin protein has been shown previously to be involved in cell adhesion mediated through the cadherin family of cell surface adhesion molecules. The high frequency of mutations found in members of cellular adhesion complexes in a variety of cancers suggests that these molecules may play a role in development of the malignant phenotype.

Original languageEnglish
Pages (from-to)1185-1192
Number of pages8
JournalJournal of Experimental Medicine
Volume183
Issue number3
DOIs
Publication statusPublished - 1996 Mar 1
Externally publishedYes

Fingerprint

Melanoma-Specific Antigens
Tumor-Infiltrating Lymphocytes
Catenins
HLA-A24 Antigen
Melanoma
Peptides
Genes
Complementary DNA
Clone Cells
Antigens
T-Lymphocyte Epitopes
Competitive Binding
Cell Adhesion Molecules
Neoplasm Antigens
Mutation Rate
Cadherins
Phenylalanine
Gene Library
Cell Adhesion
Base Pairing

ASJC Scopus subject areas

  • Immunology

Cite this

Robbins, P. F., El-Gamil, M., Li, Y. F., Kawakami, Y., Loftus, D., Appella, E., & Rosenberg, S. A. (1996). A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. Journal of Experimental Medicine, 183(3), 1185-1192. https://doi.org/10.1084/jem.183.3.1185

A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. / Robbins, Paul F.; El-Gamil, Mona; Li, Yong F.; Kawakami, Yutaka; Loftus, Douglas; Appella, Ettore; Rosenberg, Steven A.

In: Journal of Experimental Medicine, Vol. 183, No. 3, 01.03.1996, p. 1185-1192.

Research output: Contribution to journalArticle

Robbins, PF, El-Gamil, M, Li, YF, Kawakami, Y, Loftus, D, Appella, E & Rosenberg, SA 1996, 'A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes', Journal of Experimental Medicine, vol. 183, no. 3, pp. 1185-1192. https://doi.org/10.1084/jem.183.3.1185
Robbins, Paul F. ; El-Gamil, Mona ; Li, Yong F. ; Kawakami, Yutaka ; Loftus, Douglas ; Appella, Ettore ; Rosenberg, Steven A. / A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. In: Journal of Experimental Medicine. 1996 ; Vol. 183, No. 3. pp. 1185-1192.
@article{f2e35f2ec327443ba660ea3453336111,
title = "A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes",
abstract = "A number of antigens recognized by tumor-reactive T cells have recently been identified. The antigens identified in mouse model systems appear, with one exception, to represent thee products o mutated genes. In contrast, most of the antigens recognized by human tumor-reactive C cells reported to date appear to represent the products of non-mutated genes. Here we report the isolation o a cDNA clone encoding β-catenin, which was shown to be recognized by the tumor-infiltrating lymphocyte (TIL) 1290, a HLA-A24 restricted melanoma-specific CTL line from patient 888. Thee cDNA clone, which was isolated from thee autologous melanoma cDNA library, differed by a single base pair from the published β-catenin sequence, resulting in a change from a serine to a phenylalanine residue at position 37. Normal tissues from this patient did not express the altered sequence, nor did 12 allogeneic melanomas, indicating that this represented a unique mutation in this patient's melanoma. A peptide corresponding to the sequence between amino acids 29 and 37 of the mutant gene product was identified as the T cell epitope recognized by TIL 1290. The observation that HLA-A24 binding peptides contain an aromatic or hydrophobic residue at position 9 suggested that the change at position 37 may have generated a peptide (SYLDSGIHF) which was capable of binding to HLA-A24, and a competitive binding assay confirmed this hypothesis. The β-catenin protein has been shown previously to be involved in cell adhesion mediated through the cadherin family of cell surface adhesion molecules. The high frequency of mutations found in members of cellular adhesion complexes in a variety of cancers suggests that these molecules may play a role in development of the malignant phenotype.",
author = "Robbins, {Paul F.} and Mona El-Gamil and Li, {Yong F.} and Yutaka Kawakami and Douglas Loftus and Ettore Appella and Rosenberg, {Steven A.}",
year = "1996",
month = "3",
day = "1",
doi = "10.1084/jem.183.3.1185",
language = "English",
volume = "183",
pages = "1185--1192",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "3",

}

TY - JOUR

T1 - A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

AU - Robbins, Paul F.

AU - El-Gamil, Mona

AU - Li, Yong F.

AU - Kawakami, Yutaka

AU - Loftus, Douglas

AU - Appella, Ettore

AU - Rosenberg, Steven A.

PY - 1996/3/1

Y1 - 1996/3/1

N2 - A number of antigens recognized by tumor-reactive T cells have recently been identified. The antigens identified in mouse model systems appear, with one exception, to represent thee products o mutated genes. In contrast, most of the antigens recognized by human tumor-reactive C cells reported to date appear to represent the products of non-mutated genes. Here we report the isolation o a cDNA clone encoding β-catenin, which was shown to be recognized by the tumor-infiltrating lymphocyte (TIL) 1290, a HLA-A24 restricted melanoma-specific CTL line from patient 888. Thee cDNA clone, which was isolated from thee autologous melanoma cDNA library, differed by a single base pair from the published β-catenin sequence, resulting in a change from a serine to a phenylalanine residue at position 37. Normal tissues from this patient did not express the altered sequence, nor did 12 allogeneic melanomas, indicating that this represented a unique mutation in this patient's melanoma. A peptide corresponding to the sequence between amino acids 29 and 37 of the mutant gene product was identified as the T cell epitope recognized by TIL 1290. The observation that HLA-A24 binding peptides contain an aromatic or hydrophobic residue at position 9 suggested that the change at position 37 may have generated a peptide (SYLDSGIHF) which was capable of binding to HLA-A24, and a competitive binding assay confirmed this hypothesis. The β-catenin protein has been shown previously to be involved in cell adhesion mediated through the cadherin family of cell surface adhesion molecules. The high frequency of mutations found in members of cellular adhesion complexes in a variety of cancers suggests that these molecules may play a role in development of the malignant phenotype.

AB - A number of antigens recognized by tumor-reactive T cells have recently been identified. The antigens identified in mouse model systems appear, with one exception, to represent thee products o mutated genes. In contrast, most of the antigens recognized by human tumor-reactive C cells reported to date appear to represent the products of non-mutated genes. Here we report the isolation o a cDNA clone encoding β-catenin, which was shown to be recognized by the tumor-infiltrating lymphocyte (TIL) 1290, a HLA-A24 restricted melanoma-specific CTL line from patient 888. Thee cDNA clone, which was isolated from thee autologous melanoma cDNA library, differed by a single base pair from the published β-catenin sequence, resulting in a change from a serine to a phenylalanine residue at position 37. Normal tissues from this patient did not express the altered sequence, nor did 12 allogeneic melanomas, indicating that this represented a unique mutation in this patient's melanoma. A peptide corresponding to the sequence between amino acids 29 and 37 of the mutant gene product was identified as the T cell epitope recognized by TIL 1290. The observation that HLA-A24 binding peptides contain an aromatic or hydrophobic residue at position 9 suggested that the change at position 37 may have generated a peptide (SYLDSGIHF) which was capable of binding to HLA-A24, and a competitive binding assay confirmed this hypothesis. The β-catenin protein has been shown previously to be involved in cell adhesion mediated through the cadherin family of cell surface adhesion molecules. The high frequency of mutations found in members of cellular adhesion complexes in a variety of cancers suggests that these molecules may play a role in development of the malignant phenotype.

UR - http://www.scopus.com/inward/record.url?scp=0029669950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029669950&partnerID=8YFLogxK

U2 - 10.1084/jem.183.3.1185

DO - 10.1084/jem.183.3.1185

M3 - Article

C2 - 8642260

AN - SCOPUS:0029669950

VL - 183

SP - 1185

EP - 1192

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 3

ER -